AirXpanders Places 4,000th AeroForm Implant


AirXpanders Inc, a medical device company focused on the design, manufacture, sale and distribution of the AeroForm Tissue Expander System, announces the 4,000th commercial worldwide placement of the AeroForm Tissue Expander was recently implanted in a patient for post-mastectomy, two-stage breast reconstruction.

“This is a great accomplishment for our company, and an empowering experience for the patient,” says Frank Grillo, president and CEO of AirXpanders, in a media release. “Since we commercialized our technology in Australia in 2015 and the US in 2017, we have seen rapid adoption of the AeroForm Tissue Expander System.

“With AeroForm, patients have the ability to control their own tissue expansion and preparation for the implantation of a permanent implant for breast reconstruction. The use of AeroForm is easier for the physician compared to traditional saline tissue expanders, and patients appreciate the ability to avoid several needle-sticks after surgery,” he adds.

Laurel Burk, director of marketing for AirXpanders, notes that, “Adoption of our technology continues to gain steam in the US. AeroForm is approved for use in over 200 hospitals and hospital systems in the United States, and over 80 in Australia. New US hospitals and physicians are being added monthly, which is adding to our current revenue growth and laying the foundation for future growth and the opportunity for AeroForm to become the standard of care for tissue expansion in breast reconstruction.”

“During the second and third quarter, we have seen continued progress on our key goals as a newly refocused company,” Grillo continues. “We have completed the restructuring of our sales force in the US, and now every established territory has a dedicated sales representative. Our progress in driving adoption in the US is meeting or exceeding our expectations in each territory, and our focus on expense controls and working capital management continues.

“Consistent with our Q3 results, we are confident that our Q4 results, to be released in January 2019, will show another reduction in cash burn, as well as continued US revenue growth. Our business is on track, adoption is growing, and cash burn is slowing versus prior quarters,” he continues, in the release.

[Source(s): AirXPanders Inc, PR Newswire]

8 Plastic Surgery Procedures Trending Now: Bizarre Or Not?

While names like liposuction or breast augmentation are well known, other less common procedures are apparently making their way into the plastic surgery industry.

According to the latest International Society of Aesthetic Plastic Surgery (ISAPS) report , such procedures as labiaplasty or vaginal tightening are among the fastest growing practices in the world.

Here’s our list of eight plastic surgery procedures that more and more people are lining up to take.

RealSelf Debuts Hall of Fame to Honor Ratings and Education

RealSelf Hall of Fame Unveiled

RealSelf announces the debut of the RealSelf Hall of Fame, an honor recognizing more than 1,000 board-certified aesthetic doctors from 402 cities across the United States, the United Kingdom, Canada, and Australia for their high patient ratings and commitment to consumer education.

For 8 years, the annual RealSelf 100 and 500 awards recognized doctors with outstanding records of high patient ratings who have given back to the RealSelf community by providing credible, valuable insights in response to consumer questions about elective cosmetic treatments ranging from surgical procedures to minimally invasive technologies to cosmetic dentistry. For the first time ever, RealSelf celebrates the Hall of Fame, a culmination of 8 years of recognitions made through the RealSelf 100 and 500 awards program, according to RealSelf in a media release.

“Making the RealSelf Hall of Fame requires a commitment to helping patients make informed and confident choices,” says Dr Lara Devgan, RealSelf chief medical officer and board-certified plastic surgeon, in the release. “From answering consumer questions and sharing before and after photos to encouraging patients to leave open and honest reviews, the valuable insights this group provides help make it possible for RealSelf to bring transparency to the medical aesthetics industry.”

To be included in the RealSelf Hall of Fame, doctors must have received a RealSelf 100 or RealSelf 500 award in the past, the release explains. The awards program, which first launched in 2010, honors the top-rated and most engaged board-certified aesthetic doctors on RealSelf. Doctors are ranked in three categories: earning patient reviews, answering consumer questions, and sharing before and after treatment photos. In order to be recognized in any given year, doctors must maintain the distinction of Top Doctor or Top Contributor and uphold an average rating above four stars.

“The RealSelf Hall of Fame honors the achievements of board-certified aesthetic doctors who consistently put the consumer first,” states Tom Seery, founder and CEO of RealSelf. “It’s my pleasure to recognize this elite group of doctors for their significant contributions on RealSelf and their high standards in patient satisfaction.”

“As RealSelf grows and continues to evolve how we help consumers make smart and confident decisions, we are also evaluating how we recognize our medical community,” Seery adds. “We look forward to announcing new plans for RealSelf awards and recognitions in 2019.”

[Source(s): RealSelf, PR Newswire]

MedShift Partners with Merz North America

MedShift, located in Charlotte, NC, announces a 5-year-long strategic partnership with Raleigh, NC-based Merz North America.

The partnership between MedShift and Merz North America is powered by both companies’ equal and respective appreciation for cutting-edge product development innovation for physicians and the drive to improve health and quality of life for patients, according to a media release from MedShift.

“Following the successful rebrand of vConfidence, MedShift is excited to expand our portfolio with this partnership to offer more valuable and innovative solutions for today’s woman,” says MedShift’s CEO, Brian Phillips.

This partnership will bring more awareness to Cellfina, a state-of-the-art, FDA-cleared device that provides long-lasting reversal of cellulite. The device shows 5 years of sustained results with no recurring symptoms. As part of the partnership, MedShift will launch Effronté as a means by which to make the Cellfina technology more accessible to more women, the release continues.

“This partnership is going to do great things for both Merz North America and MedShift,” states MedShift Medical Director Dr Bill Kortesis, FACS, and board-certified plastic surgeon. “We’re looking forward to seeing what’s possible when we combine the Cellfina device with MedShift’s technology.”

This partnership is part of a continued investment by MedShift in women’s health. Since 2015, MedShift has invested over $10,000,000 in procedures to improve and enhance women’s lives.

“Our goal with this partnership and the Effronté brand is to make women feel more confident,” Phillips adds. “Because, when a woman feels like that, she’s unstoppable.”

[Source(s): MedShift, PR Newswire]

The HydraFacial Company and SENTÉ Partner, Launch Booster

The HydraFacial Company announces a new partnership with SENTÉ, a specialty aesthetics company.

This partnership aims to offer HydraFacial clients and consumers the opportunity to experience SENTÉ’s patented Sulfated Glycosaminoglycan (SuGAG) analog technology developed to deliver rapid skin rejuvenation.

Through the partnership, SENTÉ and HydraFacial are launching a new booster, SENTÉ Dermal Repair, to medical providers. The SENTÉ booster can be added to HydraFacial treatments providing additional customization and targeted results for patients including increased superficial and deep hydration, minimizing the appearance of fine lines and wrinkles and redness reduction, explains a media release from The HydraFacial Company.


“We are always happy to partner with brands that work synergistically with the HydraFacial treatment to provide the best possible experience for our partners and consumers,” says Clint Carnell, chief executive officer of The HydraFacial Company. “Partnering with SENTÉ was a perfect fit because the treatment is innovative and provides proven skin improvements, just like HydraFacial. We know that our partners and consumers will love the SENTÉ booster and the benefits it will provide.”

“As a first for SENTÉ, this partnership will contribute to our overall strategy to further educate on the brand’s advanced Sulfated Glycosaminoglycan analog technology,” states Laurent Combredet, president and chief executive officer of SENTÉ, in the release. “By partnering with a leading skin care company like HydraFacial, we are able to bring our unparalleled product formulations to a wider range of skin care users across the country.”

[Source(s): The HydraFacial Company, PR Newswire]

Doctors, Patients Raise Alarms About Cancer Linked to Breast Implants

Women choose to get breast implants either for breast reconstruction after mastectomy or for cosmetic reasons. The American Society of Plastic Surgeons reported 400,000 breast implant procedures took place in 2017, up nearly 40 percent since 2000.

It’s taken several years to gather data but the FDA now believes that textured breast implants may be more likely to cause ALCL, although it says smooth implants are also linked to an increased risk. The trouble is that there’s no organized effort to put together data from people who have implants and those who have developed ALCL.

Dermatologists Debunk Common Misconceptions About Laser Hair Removal

When performed by a doctor, laser hair removal is a safe, effective, and permanent solution for removing unwanted face and body hair. This clinically tested, FDA-approved treatment has been around since the mid-1990s and is a very common procedure among young adults ages 20 to 45. However, the results don’t occur overnight, say dermatologists from the American Academy of Dermatology, and in inexperienced hands, laser hair removal can be dangerous.

Performed improperly, the treatment can result in burns, permanent skin color changes, and even scars. To reduce the risk of possible side effects and ensure an effective treatment, the AAD recommends that consumers only seek laser hair removal from a medical doctor who is extremely skilled in using lasers and has in-depth knowledge of the skin.

For more information and to read the full press release, visit American Academy of Dermatology.

TOPIX Pharmaceuticals Launches Customizable Professional Peels Line

TOPIX Pharmaceuticals Inc announces the launch of Topix Professional Peels, with a configurable peel portfolio that allows providers the flexibility to choose specific peel ingredients and strengths to address individual patient skin concerns.

According to a company news release, Topix Professional Peels is a medically exclusive line that includes retinol- and acid-based peels, designed with the highest quality pharmaceutical-grade ingredients to deliver safe and effective results for all skin types. These in-office use only peels are superficial peels, available to treat a myriad of skin conditions, including acne, hyperpigmentation, rosacea and aging:

  • Retinol Peel, 6% – A mild superficial peel and rapid exfoliator for the treatment of dry, dull and/or pigmented skin. For all skin types.
  • Retinol Peel Accelerator – A mild superficial peel and rapid exfoliator for the treatment of dry, dull and/or pigmented skin. For all skin types.
  • Universal Peel – A mild superficial peel and rapid exfoliator for the treatment of dry, dull skin. For all skin types.
  • Intermediate Peel – A medium superficial peel for the treatment of pigmentation, aiding in the enhancement of brightening therapies. For Fitzpatrick skin types I-III.
  • Mandelic Acid, 40% – A mild superficial peel and exfoliator for the treatment of hyperpigmented, photodamaged, or acne-prone skin. For all skin types.
  • Salicylic Acid, 20% – A mild superficial peel and rapid exfoliator for the treatment of dry, dull skin. For all skin types.
  • Glycolic, 25% – Lactic, 25% – A mild superficial peel for the treatment of pigmented skin and to enhance brightening therapies. For Fitzpatrick skin types I-III.
  • Lactic Acid, 20% – A mild superficial peel and hydrator for the treatment of dry, dull skin. Aids in the reduction of surface oils and blemishes. For all skin types, including rosacea patients.

Comprehensive conjunctive treatment products are available to complement Topix Professional Peels, including Prep Pads, Pre Peel Cleansing Pads and Peel Neutralizer spray.

As part of its commitment to partnering with physicians to provide advanced, innovative skin solutions, Topix offers at-home regimens for post-peel care and a new line of in-office back bar products that cleanse, soothe, hydrate, and protect, available micro-branded. A customized at-home post-peel maintenance regimen is strongly recommended after chemical peels.

Dedicated to providing complete support to physician partners, Topix Professional Peels are available micro-branded, per the release.

[Source: Kelz PR]

Revance Therapeutics Inc Announces Study Results and a License Agreement for RT002

Revance Therapeutics Inc, a Newark, Calif-based developer of neuromodulators for the treatment of aesthetic and therapeutic conditions, announces two pieces of company news regarding RT002.

RT002 is the Newark, Calif-based company’s long-acting neuromodulator DaxibotulinumtoxinA for Injection.

First, Revance shares SAKURA Phase 3 study results of RT002.

And second, the company announces it has entered into a license agreement with Fosun Pharma to market RT002 in China.

For more information, visit Revance Therapeutics Inc.

[Source(s): Revance Therapeutics Inc, Business Wire]